Milan

• A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanc … Ended recruitment
  2024-512378-91-00 4 2022-06-24 Unresectable or Advanced Melanoma
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended recruitment
  2023-505974-14-00 5 2022-06-23 Multiple Sclerosis (MS)
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat … Ended recruitment
  2023-509345-12-00 5 2022-06-22 Multiple Sclerosis
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Myelin Oligodendrocyte Gly … Ended recruitment
  2023-507196-22-00 5 2022-06-20 Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD
• A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, … Ended recruitment
  2024-510800-35-00 5 2022-06-17 Relapsed or Refractory Multiple Myeloma (RRMM)
• GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately t … Ended recruitment
  2023-504737-41-00 5 2022-06-10 Moderately to Severely Active Crohn's Disease
• A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cho … Ended recruitment
  2023-505764-11-00 4 2022-06-10 Pruritus associated with Primary Sclerosing Cholangitis (PSC)
• A study to investigate the short- and long-term safety and tolerability of the drug SNDX-5613 in Patients with Relapsed/Refractory Leukemias … Ended recruitment
  2024-513759-34-00 7 2022-05-31 Relapsed or Refractory Acute Leukemias
• A late stage clinical trial to investigate the efficacy and safety of Osimertinib versus Placebo in patients with stage IA2-IA3 non-small ce … Ended recruitment
  2023-509943-28-00 5 2022-05-18 Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (
• A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended recruitment
  2023-507795-51-00 5 2022-05-17 atherosclerotic heart and blood vessel disease (the narrowing of arter
• Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA) Ended recruitment
  2023-508536-64-00 9 2022-05-17 Metastatic Prostate Cancer
• A Study to Evaluate Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related … Ended recruitment
  2023-507131-38-00 5 2022-05-16 Neovascular Age-Related Macular Degeneration (nAMD)
• Genetic vaccine for the treatment of microsatellite unstable solid tumors Ended recruitment
  2024-514723-42-00 9 2022-05-05 Locally advanced unresectable or metastatic, microsatellite instabilit
• A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant Ended recruitment
  2023-508897-27-00 5 2022-04-28 Multiple Myeloma
• A study in patients with skin cancer Ended recruitment
  2024-516914-39-00 5 2022-04-27 Metastatic or unresectable melanoma
• Study to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopeni … Ended recruitment
  2024-513147-90-00 5 2022-04-26 Primary Immune Thrombocytopenia
• A study to evaluate KER-050 as a monotherapy or in combination with Ruxolitinib in Myelofibrosis. Ended recruitment
  2023-507468-38-00 4 2022-04-22 Myelofibrosis
• A Study to Evaluate Overall Health, Physical Activity and Joint Outcomes, in Participants with Severe or Moderate Hemophilia A without FVIII … Ended recruitment
  2023-505747-40-00 6 2022-04-20 Severe or Moderate Hemophilia A
• Open-Label and Long-term Extension Study with Dersimelagon (MT-7117) in Subjects with EPP or XLP Ended recruitment
  2024-514466-38-00 5 2022-04-19 Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
• A Phase 2 study of INBRX-109 in adults with a type of unresectable or metastasized cancer of the bones and joints (Conventional Chondrosarco … Ended recruitment
  2024-517528-20-00 4 2022-04-19 Unresectable or metastatic conventional chondrosarcoma
• Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc … Ended recruitment
  2023-510097-14-00 5 2022-04-15 Patients with MMR deficient relapse or advanced / metastatic endometri
• A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Non Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE) Ended recruitment
  2024-512745-16-00 5 2022-04-13 Non–Transfusion-Dependent Alpha- or Beta-Thalassemia
• A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular A … Ended recruitment
  2023-506761-65-00 10 2022-04-08 Spinal Muscular Atrophy (SMA)
• Clinical Trial of MK-7684A with chemotherapy for extensive stage small cell lung cancer (ES-SCLC) Ended recruitment
  2023-503517-30-00 5 2022-04-01 Extensive-stage small-cell lung cancer

Showing 1,537–1,560 of 2,361 trials